Case Overview

In a decisive default judgment handed down by the Southern District of New York, BTL Industries, Inc. secured a sweeping victory against Versalini Beauty & Spa Salon, walking away with $200,000 in statutory damages, a permanent injunction, and judgment on all four causes of action. The case — BTL Industries, Inc. v. Versalini Beauty & SPA Salon, Case No. 1:23-cv-08617 — closed on July 24, 2024, just 299 days after filing, making it a notably swift resolution in the aesthetic medical device patent infringement space.

At the heart of the dispute was U.S. Patent No. 10,478,634 and the unauthorized use of BTL’s proprietary EMSCULPT® brand — an FDA-cleared body-contouring device that has reshaped the aesthetic treatment industry. For patent attorneys, IP professionals, and R&D teams operating in the medical aesthetics sector, this case delivers sharp lessons about enforcement strategy, the value of bundled IP claims, and the serious commercial consequences of unauthorized device promotion.

The Parties

The Patent at Issue

This case involved **U.S. Patent No. 10,478,634** (Application No. US16/034793), covering core technology underlying the EMSCULPT® device. The patent protects innovations in electromagnetic body-contouring methodology, providing BTL with enforceable exclusivity over a technology category generating significant commercial revenue.

• • US 10,478,634 — Technology underlying the EMSCULPT® device

The alleged infringement centered on using BTL’s patented technology and registered trademarks to promote services without being an authorized BTL provider, leading to four causes of action:

• • Patent Infringement — U.S. Patent No. 10,478,634
• • Federal Trademark Infringement — 15 U.S.C. § 1114
• • Federal Unfair Competition, False Designation of Origin & False Advertising — 15 U.S.C. § 1125
• • Common Law Trademark Infringement and Unfair Competition

Litigation Timeline & Procedural History

BTL Industries filed its complaint on September 29, 2023, in the U.S. District Court for the Southern District of New York — a strategically sound venue choice given its established IP docket, sophisticated federal judges, and jurisdictional appropriateness for a New York-based defendant.

The case was assigned to Chief Judge Lewis J. Liman, a respected jurist in the SDNY known for methodical opinions and efficient case management. The absence of a defense appearance transformed the litigation into a default judgment proceeding, with BTL filing its motion for default judgment at Docket No. 14.

A notable procedural element was the court’s grant of BTL’s Motion to Seal (Dkt. No. 20) portions of its memorandum of law and the declaration of Jason Wooden (Dkt. No. 22) — a common protective measure in cases involving proprietary commercialization data.

The Court’s Opinion and Order dated July 8, 2024, preceded the final judgment entered on July 24, 2024 — yielding a total case duration of 299 days, an efficient resolution that reflects the procedural streamlining inherent in unopposed default proceedings.

The Verdict & Legal Analysis

Outcome

Judge Liman entered judgment in favor of BTL Industries on all four causes of action:

1. Patent Infringement — U.S. Patent No. 10,478,634
2. Federal Trademark Infringement — 15 U.S.C. § 1114
3. Federal Unfair Competition, False Designation of Origin & False Advertising — 15 U.S.C. § 1125
4. Common Law Trademark Infringement and Unfair Competition

The court awarded $200,000 in statutory damages and granted a permanent injunction prohibiting Versalini from:

• • Using BTL trademarks to promote unauthorized goods or services
• • Passing off non-BTL products as genuine BTL offerings
• • Further infringing BTL’s trademarks and patent

This case established significant precedent for how patent and trademark infringement can be addressed in the aesthetic medical device industry, attracting broad attention from IP professionals and technology companies worldwide.

Key Legal Issues

The judgment arose from an infringement action in which Versalini failed to appear or mount any defense. Under Fed. R. Civ. P. 55, courts may enter default judgment when a defendant fails to plead or otherwise respond. However, default does not render judgment automatic — BTL was still required to establish jurisdictional competence, venue propriety, and a sufficient factual basis for each claim.

The court confirmed subject matter jurisdiction, personal jurisdiction, and proper venue — threshold requirements that BTL’s legal team methodically satisfied through its motion papers and Wooden declaration. The bundled approach — asserting patent infringement alongside multiple trademark and unfair competition claims — proved strategically effective, ensuring that even if one claim faced scrutiny, the overall liability framework remained robust.

The sealing of key motion papers suggests BTL’s memorandum contained commercially sensitive information about its EMSCULPT® sales figures, licensing structures, or market pricing — details that could inform competitor strategy if publicly disclosed.

This ruling has had lasting implications for how medical device IP risk is assessed in the aesthetic services industry and beyond.